Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy

Roberto Puzone, Laura Paleari, Franco Montefiore, Luca Ruggiero, Matteo Puntoni, Massimo Maffezzini, Barbara Bobbio, Paola Marroni, Roberta Libener, Pier Giacomo Betta

Research output: Contribution to journalArticle

Abstract

Background: Prostate cancer is the second most frequent cause of tumor-related deaths in men in Western countries. The selection and evaluation of new markers might help to overcome the limits of the most widely used diagnostic tool, the prostate-specific antigen (PSA) test, often combined with digital rectal examination (DRE). Osteopontin (OPN) is an integrin-binding glycoprotein that has recently been shown to be related to tumor development, progression and metastasis in both experimental and clinical studies. The present study compares plasma OPN levels and tumor presence and grade in a group of PSA/DRE-positive patients referred for diagnostic prostate biopsy. Methods: Plasma OPN levels were measured by enzyme-linked immunosorbent assay in blood samples of 194 PSA/DRE-positive patients referred for diagnostic prostate biopsy. OPN measurements were compared with PSA levels and tumor presence and grade as established by needle biopsy. Results: Plasma OPN levels were not increased in patients with prostate cancer, and in patients with high-grade prostate cancer the plasma OPN levels were not different from those in patients with low-grade or no prostate cancer. Conclusions: In PSA/DRE-positive patients referred for diagnostic prostate biopsy, OPN does not appear to be a plasma marker able to detect prostate cancer or high-grade prostate cancer.

Original languageEnglish
Pages (from-to)200-206
Number of pages7
JournalInternational Journal of Biological Markers
Volume25
Issue number4
DOIs
Publication statusPublished - Oct 2010

Keywords

  • Circulating tumor markers
  • Osteopontin
  • Prostate cancer
  • PSA

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy'. Together they form a unique fingerprint.

  • Cite this

    Puzone, R., Paleari, L., Montefiore, F., Ruggiero, L., Puntoni, M., Maffezzini, M., Bobbio, B., Marroni, P., Libener, R., & Betta, P. G. (2010). Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy. International Journal of Biological Markers, 25(4), 200-206. https://doi.org/10.5301/JBM.2010.6116